Clinical trial
Study to Determine if Contacting Patients With MTC More Frequently Results in…
NCT01298323 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT01298323 |
|---|---|
| Title | Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment |
| Official title | A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer |
| Intervention type | Behavioral, Drug |
| Interventions | Patient outreach, Vandetanib |
| Enrollment | 205 |
| Start date | Feb 25, 2011 |
| Primary completion | Apr 26, 2013 |
| Completion | Mar 13, 2025 |
| First posted | Feb 17, 2011 |
| Last update posted | Apr 24, 2025 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece and 8 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: